MIRM
Mirum Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$100.90
+0.27%Year over year
Reported trailing growth
- Revenue
- +44.0%
- EBITDA
- —
- EBIT
- -88.6%
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +21.1%
- EBITDA
- +92.9%
- EPS
- +87.9%
Three-year CAGR
- Revenue
- +89.1%
- EBITDA
- +135.1%
- EBIT
- +74.7%
- Net income
- +73.4%
- EPS
- +74.6%
- Free cash flow
- +488.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026